制备了一系列的单取代的嘧啶鎓和吡嗪鎓三氟甲磺酸酯和3,5-二取代的吡啶鎓三氟甲磺酸酯,并使用硫氧化作为模型反应,对过氧化氢的简单氧化催化剂进行了测试。它们的催化效率在很大程度上取决于取代基的类型,并且对于具有吸电子基团的衍生物而言是显着的,其反应性与黄酮盐相当,后者是氧合作用的主要有机催化剂。由于它们的高稳定性和良好的可及性,4-(三氟甲基)嘧啶鎓和3,5-二硝基吡啶鎓三氟甲磺酸盐是选择的催化剂,并显示出催化脂肪族和芳香族硫化物氧化为亚砜的作用,定量转化率高,制备产率高,并且具有优异的性能。化学选择性。K R +值(p K R + <5)和较小的负还原电位(E red > -0.5 V)。在催化氧化过程中原位形成的过氧化氢加合物充当底物氧化剂。通过在B3LYP / 6-311 ++ g(d,p)水平上的计算获得的从这些杂环氢过氧化物到硫代苯甲醚的转移的吉布斯自由能表明,它们是比烷基氢过氧化
[EN] NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES TÉTRAHYDROPYRIDOPYRIMIDINES ET TÉTRAHYDROPYRIDOPYRIDINES POUR LE TRAITEMENT ET LA PRÉVENTION D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
申请人:HOFFMANN LA ROCHE
公开号:WO2016107832A1
公开(公告)日:2016-07-07
The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.
[EN] CYCLOBUTENEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOBUTÈNE-DIONE
申请人:PFIZER LTD
公开号:WO2010131145A1
公开(公告)日:2010-11-18
The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.
Two-Phase Oxidations with Aqueous Hydrogen Peroxide Catalyzed by Amphiphilic Pyridinium and Diazinium Salts
作者:Tomáš Hartman、Jiří Šturala、Radek Cibulka
DOI:10.1002/adsc.201500687
日期:2015.11.16
Amphiphilic pyridinium and diazinium salts were shown to be effective catalysts in two-phase (water/chloroform or water/dichloromethane) sulfoxidations and N-oxidations with hydrogenperoxide under mild conditions. This unprecedented oxidation method utilizes covalent bonding of hydrogenperoxide to a simple pyridinium or diazinium nucleus to increase the lipophilicity of the hydroperoxide species
[EN] TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)MÉTHANONE À TITRE D'INHIBITEURS DE CROISSANCE DES CELLULES CANCÉREUSES
申请人:REXAHN PHARMACEUTICALS INC
公开号:WO2014143960A1
公开(公告)日:2014-09-18
Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described.
Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors
作者:Angela G. Koryakova、Yan A. Ivanenkov、Elena A. Ryzhova、Elena A. Bulanova、Ruben N. Karapetian、Olga V. Mikitas、Eugeny A. Katrukha、Vasily I. Kazey、Ilya Okun、Dmitry V. Kravchenko、Yan V. Lavrovsky、Oleg M. Korzinov、Alexandre V. Ivachtchenko
DOI:10.1016/j.bmcl.2007.11.121
日期:2008.6
heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamide inhibitors of GSK-3beta kinase are described. The inhibitory activity of the synthesized compounds is highly dependent on the character of substituents in the phenylring and the nature of terminal heterocyclic fragment of the core molecular scaffold. The most potent compounds from this series contain 3,4-di-methyl